Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Richards, D. A.
Nemunaitis, J. J.
Vukelja, S. J.
Hagenstad, C. T.
Campos, L. T.
Letzer, J. P.
Hermann, R. C.
Sportelli, P.
Gardner, L. R.
Bendell, J. C.
机构：
[1] Texas Oncol, Tyler, TX USA
[2] Crowley Canc Res Ctr, Dallas, TX USA
[3] Suburban Hematol & Oncol, Lawrencville, GA USA
[4] Oncol Consultants PA, Houston, TX USA
[5] Kalamazoo Hematol & Oncol, Kalamazoo, MI USA
[6] Northwest Georgia Oncol Ctr, Marietta, GA USA
[7] Keryx Biopharmaceut Inc, New York, NY USA
[8] Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3531
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer
    Vukelja, S.
    Richards, D.
    Campos, L. T.
    Bedell, C.
    Hagenstad, C.
    Hyman, W.
    Letzer, J.
    Gardner, L.
    Sportelli, P.
    Nemunaitis, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Results of the X-PECT study: A phase III randomized double-blind placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).
    Bendell, Johanna C.
    Ervin, Thomas J.
    Senzer, Neil N.
    Richards, Donald A.
    Firdaus, Irfan
    Lockhart, A. Craig
    Cohn, Allen Lee
    Saleh, Mansoor N.
    Gardner, Lesa R.
    Sportelli, Peter
    Eng, Cathy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Safety and pharmacokinetic (PK) study of perifosine plus capecitabine (P-CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC)
    Greco, F. A.
    Infante, J. R.
    Burris, H. A.
    Jones, S. F.
    Kolesar, J.
    Gardner, L. R.
    Sportelli, P.
    Bendell, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer
    Bendell, Johanna C.
    Nemunaitis, John
    Vukelja, Sasha J.
    Hagenstad, Christopher
    Campos, Luis T.
    Hermann, Robert C.
    Sportelli, Peter
    Gardner, Lesa
    Richards, Donald A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (33) : 4394 - 4400
  • [5] SUBSET ANALYSIS OF 5-FU REFRACTORY PATIENTS FROM A RANDOMIZED PH II STUDY OF PERIFOSINE plus CAPECITABINE (P-CAP) VS. PLACEBO plus CAPECITABINE (CAP) IN PATIENTS WITH 2ND OR 3RD LINE METASTATIC CRC
    Hoff, P.
    Richards, D.
    Nemunaitis, J.
    Vukelja, S.
    Hagenstad, C.
    Campos, L.
    Letzer, J.
    Sportelli, P.
    Gardner, L.
    Bendell, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 16 - 16
  • [6] Phase I/II study of trimetrexate (TMTX) and capecitabine (CAP) as second and third-line therapy in patients with advanced colorectal cancer (CRC).
    Matin, K
    Ramanathan, RK
    Jacobs, SA
    Wong, MK
    Earle, M
    Evans, T
    Troetschel, K
    Ferri, W
    Friedland, D
    Wieand, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 287S - 287S
  • [7] Capecitabine plus irinotecan plus bevacizurnab as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC): preliminary phase II study results
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 256 - 257
  • [8] A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer
    Choi, Dae Ro
    Yoon, Sang Nam
    Kim, Hyeong Su
    Kim, Jung Han
    Kim, Kwang Yong
    Kim, Byung Chun
    Choi, Young Kyun
    Kim, Jin Bae
    Han, Boram
    Song, Hun Ho
    Zang, Dae Young
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 639 - 643
  • [9] A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer
    Dae Ro Choi
    Sang Nam Yoon
    Hyeong Su Kim
    Jung Han Kim
    Kwang Yong Kim
    Byung Chun Kim
    Young Kyun Choi
    Jin Bae Kim
    Boram Han
    Hun Ho Song
    Dae Young Zang
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 639 - 643
  • [10] X-PECT STUDY RESULTS: A PHASE III RANDOMIZED STUDY OF PERIFOSINE PLUS CAPECITABINE VS. PLACEBO PLUS CAPECITABINE IN REFRACTORY MCRC PATIENTS
    Bendell, Johanna
    Ervin, Thomas
    Senzer, Neil
    Richards, Donald
    Firdaus, Irfan
    Lockhart, A. Craig
    Cohn, Allen
    Saleh, Mansoor
    Sportelli, Peter
    Gardner, Lesa
    Eng, Cathy
    ANNALS OF ONCOLOGY, 2012, 23 : 15 - 15
12345